CatalystFDA/Bio

Cullinan, Taiho's Zipalertinib - Chemotherapy Combo Meets Key Goal In Phase 3 NSCLC Trial; Stock Up

What changed

Why it matters

Cullinan, Taiho's Zipalertinib - Chemotherapy Combo Meets Key Goal In Phase 3 NSCLC Trial; Stock Up — impact context not separately stored; see What changed.

Sources

eodhd